Esketamine (Spravato) for Treatment Resistant Depression

esketamine (spravato) treatment resistant depression

The Disease Burden
Esketamine (Spravato) by Johnson and Johnson, received local market authorization in October 2021 for use ‘with an oral antidepressant (SSRI or SNRI) in treatment-resistant depression (TRD)’, which is defined as major depressive disorder (MDD) in adults who have not responded adequately to at least . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

The Benefits of Acupuncture for Pain Relief

Acupuncture is a safe and effective alternative to pain medications for those looking for long-lasting pain relief. Learn about the benefits of acupuncture for pain relief, how it works, and its growing popularity as a form of alternative medicine globally.

Read More »
frozen shoulder
Frozen Shoulder

Frozen shoulder is a condition that leads to shoulder pain and stiffness. It is also known as adhesive capsulitis or inflammation of the shoulder joint

Read More »